Most biologics and many sterile drugs cannot survive heat, so filtration is the step that makes them sterile. Sterile filtration in pharmaceutical manufacturing is deceptively simple: push the fluid through a membrane fine enough to hold back microorganisms. In practice it depends on the right filter train, a validated filter, a mycoplasma strategy where cells are involved, and integrity testing that proves the filter was intact when it mattered. This article walks through each of those.
The sterile filtration train in pharmaceutical manufacturing
A sterilising filter is rarely used on its own. Placed directly on a crude process stream it would block quickly, raising cost and risking the batch. Instead, filters are arranged in a sequence where each stage protects the next.
- Clarification removes cells and debris after harvest, typically with depth filters.
- Prefiltration removes finer particles and colloids that would foul the final membrane.
- Bioburden reduction lowers the microbial load before hold steps or before the final filter.
- Sterile filtration produces the sterile fluid, usually as close to the point of fill as possible.
- Mycoplasma removal is added where cell culture media or other fluids could carry mycoplasma.
Gas and vent filters sit alongside the liquid train, protecting bioreactors, tanks and lines from airborne contamination as they breathe.
What makes a filter sterilising grade
Filters are sold with a pore-size rating, commonly 0.2 or 0.22 µm for sterile filtration. The rating is a convenient label, not the proof. A sterilising-grade filter is defined by performance: it must retain a standardised bacterial challenge and produce a sterile filtrate.
The standard challenge organism is Brevundimonas diminuta, a small bacterium chosen because it represents a worst case for retention. Manufacturers qualify their filters with this test, and users confirm that the qualification applies to their process through process-specific validation, which checks the filter with the actual product, under the actual pressure, flow, temperature and contact time. Validation also covers compatibility, extractables and leachables, and the effect of the product on the filter's integrity test values.
Mycoplasma: the organism that slips through
Mycoplasma are among the smallest free-living organisms. They lack a cell wall and can change shape, which lets them pass through membranes rated for bacteria. They are a significant risk in cell culture: contamination can go unnoticed, alter cell behaviour and compromise a product.
Where mycoplasma is a realistic risk, particularly in cell culture media and supplements, manufacturers add mycoplasma-retentive filtration. These filters are commonly rated at 0.1 µm and are validated with a mycoplasma challenge. Because finer membranes filter more slowly, the filter area and prefiltration need to be sized carefully to keep throughput acceptable.
Integrity testing: proving the filter was intact
A validated filter protects the product only if it is intact during use. Integrity tests are non-destructive checks that confirm this, correlated during validation to the bacterial retention test.
- Bubble point raises gas pressure on a wetted membrane until liquid is forced out of the largest pores. A value below the specification indicates a defect.
- Diffusion (forward flow) measures gas flow through the wetted membrane at a pressure below the bubble point. It is often preferred for larger filter areas.
- Pressure hold measures pressure decay upstream of the filter over time.
Sterilising filters are tested after use to confirm they stayed intact throughout filtration. EU GMP Annex 1 also expects a test before use and after sterilisation of the assembly, known as PUPSIT, to detect damage caused by sterilisation or installation. Designing assemblies with sterile connections for the test fluid and a downstream vent or bag makes PUPSIT practical without compromising sterility.
Sizing filters and scaling up
Filter area is a balance. Too little and the filter blocks before the batch is finished, forcing a change mid-process; too much and the cost, hold-up volume and product loss rise. The usual approach is to size from small-scale trials with the real process fluid.
Two small-scale methods are common. A constant-flow study records the rise in pressure as fluid passes through a small disc of the membrane, which reflects how most production filters are operated. A constant-pressure study, often called a Vmax test, measures how the flow rate decays and predicts the maximum volume a given area can process. In both cases, a safety factor is applied to cover variation between batches and filter lots.
Scale-up works best when the same membrane and device format family are used from development to production, so that small-scale results translate predictably. The prefilter and the final filter should be sized together: a better prefilter often saves more final-filter area than it costs.
Process conditions matter as much as area. Temperature changes viscosity, and viscosity changes flux. Protein concentration, pH and conductivity affect fouling and binding. Hold times before filtration can change aggregate levels, which in turn affect how quickly the membrane blocks. Record these conditions in the sizing study so the production filter is chosen for the process as it really runs.
Common problems and how to avoid them
| Problem | Typical cause | Mitigation |
|---|---|---|
| Premature blocking | Too little prefiltration, high particle load | Add or resize prefilters; review the filter train |
| Failed post-use integrity test | Wetting problems, product residue, real damage | Flush thoroughly, use the validated wetting fluid, investigate before retesting |
| Product binding | Adsorption of protein or preservative to the membrane | Choose a low-binding membrane, flush and validate recovery |
| Extractables concerns | New materials or long contact times | Use supplier data and process-specific assessment |
| Mycoplasma risk overlooked | Media filtered only at 0.2 µm | Add mycoplasma-retentive filtration where cell culture is involved |
Filtration and single-use systems
Filtration is increasingly delivered as part of pre-sterilised single-use assemblies, which combine filters, tubing, connectors and bags in one validated unit. They reduce cleaning and changeover work and can be designed around PUPSIT from the start. For a closer look at when single-use makes sense, see our article on single-use bioprocessing.
How Arab Lab supports sterile filtration
Parker provides biopharmaceutical liquid and gas filters and housings for the whole sequence, from clarification through bioburden reduction to sterile filtration and mycoplasma removal, and incorporates SciLog technology into automated single-use bioprocessing systems. Arab Lab supplies these across the UAE, Saudi Arabia and Egypt. Explore process filtration and single-use systems, or send your process step, fluid and flow rate through the contact page to discuss the right filter train.
